$7.30
-0.31[-4.07%]
At close: Apr 19
$7.30
0[0.00%]
After Hours: 4:00PM EDT
Maravai LifeSciences
(NASDAQ:MRVI)Maravai LifeSciences Stock (NASDAQ:MRVI), Analyst Ratings, Price Targets, Predictions
Maravai LifeSciences Holdings Inc has a consensus price target of $18.07, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from Craig-Hallum, RBC Capital, and Stifel on April 10, 2024, February 23, 2024, and February 23, 2024. With an average price target of $13 between Craig-Hallum, RBC Capital, and Stifel, there's an implied 78.08% upside for Maravai LifeSciences Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Craig-Hallum
RBC Capital
Stifel
B of A Securities
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Maravai LifeSciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 105.48% | Craig-Hallum | Christian Schwab | → $15 | Initiates | → Buy | Get Alert |
| 02/23/2024 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 91.78% | RBC Capital | Conor McNamara | $12 → $14 | Maintains | Outperform | Get Alert |
| 02/23/2024 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 36.99% | Stifel | Daniel Arias | $11 → $10 | Maintains | Buy | Get Alert |
| 12/12/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 9.59% | B of A Securities | Michael Ryskin | $10 → $8 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | -4.11% | Goldman Sachs | Matthew Sykes | $8 → $7 | Maintains | Neutral | Get Alert |
| 11/09/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 50.68% | Morgan Stanley | Tejas Savant | $12 → $11 | Maintains | Overweight | Get Alert |
| 08/09/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 64.38% | Morgan Stanley | Tejas Savant | $27 → $12 | Maintains | Overweight | Get Alert |
| 08/08/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 132.88% | Deutsche Bank | Justin Bowers | $23 → $17 | Maintains | Buy | Get Alert |
| 08/08/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 146.58% | RBC Capital | Conor McNamara | $20 → $18 | Maintains | Outperform | Get Alert |
| 08/08/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 9.59% | Goldman Sachs | Matthew Sykes | $12 → $8 | Maintains | Neutral | Get Alert |
| 08/08/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 50.68% | Baird | Catherine Schulte | $18 → $11 | Maintains | Outperform | Get Alert |
| 08/08/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 50.68% | Credit Suisse | Dan Leonard | $14 → $11 | Maintains | Neutral | Get Alert |
| 08/08/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | — | Keybanc | Paul Knight | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 05/23/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 91.78% | Credit Suisse | Dan Leonard | $18 → $14 | Downgrade | Outperform → Neutral | Get Alert |
| 05/10/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 78.08% | Goldman Sachs | Matthew Sykes | $16 → $13 | Maintains | Neutral | Get Alert |
| 05/10/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 269.86% | Morgan Stanley | Tejas Savant | $29 → $27 | Maintains | Overweight | Get Alert |
| 05/09/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 173.97% | RBC Capital | Conor McNamara | $22 → $20 | Maintains | Outperform | Get Alert |
| 05/09/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 78.08% | Goldman Sachs | Matthew Sykes | $16 → $13 | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2023 | MRVI | Buy Now | Maravai LifeSciences | $7.30 | 215.07% | Deutsche Bank | Justin Bowers | $25 → $23 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Maravai LifeSciences (MRVI)?
The latest price target for Maravai LifeSciences (NASDAQ: MRVI) was reported by Craig-Hallum on April 10, 2024. The analyst firm set a price target for $15.00 expecting MRVI to rise to within 12 months (a possible 105.48% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Maravai LifeSciences (MRVI)?
The latest analyst rating for Maravai LifeSciences (NASDAQ: MRVI) was provided by Craig-Hallum, and Maravai LifeSciences initiated their buy rating.
When was the last upgrade for Maravai LifeSciences (MRVI)?
The last upgrade for Maravai LifeSciences Holdings Inc happened on December 12, 2023 when B of A Securities raised their price target to $8. B of A Securities previously had a neutral for Maravai LifeSciences Holdings Inc.
When was the last downgrade for Maravai LifeSciences (MRVI)?
The last downgrade for Maravai LifeSciences Holdings Inc happened on August 8, 2023 when Keybanc changed their price target from N/A to N/A for Maravai LifeSciences Holdings Inc.
When is the next analyst rating going to be posted or updated for Maravai LifeSciences (MRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Maravai LifeSciences (MRVI) correct?
While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a initiated with a price target of $0.00 to $15.00. The current price Maravai LifeSciences (MRVI) is trading at is $7.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.